Search

Issue
Title
Authors
Albumin-bound paclitaxel in the treatment of metastatic breast cancer
Artamonova E.V.
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E.
Stereotactic biopsy of breast lesions under x-ray control
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J.
Breast cancer immunology: theory and prospects (review)
Kolyadina I.V., Poddubnaya I.V.
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
Seryakov A.P., Ovchinnikova L.K., Zabelin M.V., Yakubov T.Z., Sidorov D.B., Ovchinnikov M.V.
New possibilities of chemotherapy for anthracyclineand/or taxane-resistant breast cancer
Artamonova E.V., Manzyuk L.V.
Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study
Sultanbaev A.V., Kolyadina I.V., Menshikov K.V., Musin S.I., Nasretdinov A.F., Sultanbaeva N.I., Rakhimov R.R., Lipatov D.O., Menshikova I.A., Izmailov A.A., Lipatova E.E.
Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
Ognerubov N.A.
Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review
Imyanitov E.N.
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review
Poddubnaya I.V., Gligorov J., Zhukova L.G., Kovalenko E.I., Frolova M.A.
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population
Grechukhina K.S., Zhukova L.G.
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0
Pavlikova O.A., Poddubnaya I.V., Kolyadina I.V., Abdullaev A.G., Komov D.V., Danzanova T.Y., Sinyukova G.T., Kozlov N.A., Ganshina I.P., Zhukova L.G., Aliyeva G.S., Kerimov R.A., Gordeeva O.O.
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E.V., Manziuk L.V.
Male breast cancer: review of the literature
Nikolaev K.S., Semiglazov V.F., Semiglazov V.V.
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Prognostic significance of androgen receptor expression in triple-negative breast cancer
Panchenko I.S., Panchenko S.V., Sharafutdinov M.G., Rodionov V.V., Kometova V.V., Burmenskaya O.V.
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L.G., Bolotina L.V., Dvornichenko V.V., Fadeeva N.V., Ganshina I.P., Grechukhina K.S., Hasanova A.I., Kislov N.V., Kudryavtsev I.Y., Manikhas A.G., Musaeva N.E., Nizhegorodtseva A.A., Sadikova O.E., Sakaeva D.D., Snegovoy A.V., Stroyakovskiy D.L., Tjulandin S.A., Trishkina E.A., Vladimirova L.I., Volkov N.M., Kostalanova Y.V.
Predictive modeling of the probability of gynecological complications of tamoxifen therapy: A prospective study
Golubenko E.O., Savelyeva M.I., Korennaya V.V., Podzolkova N.M., Valiev T.T.
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study
Chulkova S.V., Sholokhova E.N., Poddubnaya I.V., Stilidi I.S., Tupitsyn N.N.
Triple-negative breast cancer: new options for systemic targeted therapy. A review
Andreev D.A., Zavyalov A.A.
Breast cancer immunophenotype and its relationship with haematopoiesis
Ryabchikov D.A., Chulkova S.V., Shamilov F.A., Chanturia N.V., Zheltikov S.D., Tupitsyn N.N.
Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform
Board E.
The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer
Tabakov D.V., Zabotina T.N., Chanturia N.V., Zakharova E.N., Vorotnikov I.K., Selchuk V.Y., Sokolovskiy V.V., Petrovsky A.V.
Ribociclib in 1st line HR+ breast cancer treatment
Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V.
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
Artamonova E.V.
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V.
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer
Semiglazova T.Y., Klyuge V.A., Semiglazov V.V., Teletaeva G.M., Krivorotko P.V., Dashyan G.A., Paltuev R.M., Tkachenko E.V., Donskikh R.V., Semiglazov V.F.
The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients
Frank G.A., Ilatovskaia M.E., Andreeva I.I., Zavalishina L.E.
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I?
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V.
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A., Koroleva N.I.
101 - 133 of 133 Items << < 1 2 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"